Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12,728 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prostate-specific membrane antigen positron emission tomography-computed tomography use prior to systemic therapy in metastatic castration-resistant prostate cancer.
Kelly R, Jensen A, Karunaratna N, Wong S, Shapiro J, Weickhardt A, Parente P, Azad AA, Uccellini A, Torres J, Parnis F, Goh J, Kwan EM, Brown S, Steer C, Warren M, Gibbs P, Tran B, Anton A. Kelly R, et al. Among authors: brown s. BJU Int. 2023 Feb;131(2):179-182. doi: 10.1111/bju.15930. Epub 2022 Nov 30. BJU Int. 2023. PMID: 36371671 No abstract available.
Real-world clinical outcomes and cost estimates of metastatic castration-resistant prostate cancer treatment: does sequencing of taxanes and androgen receptor-targeted agents matter?
Pereira-Salgado A, Anton A, Franchini F, Mahar RK, Kwan EM, Wong S, Shapiro J, Weickhardt A, Azad AA, Spain L, Gunjur A, Torres J, Parente P, Parnis F, Goh J, Steer C, Brown S, Gibbs P, Tran B, IJzerman M. Pereira-Salgado A, et al. Among authors: brown s. Expert Rev Pharmacoecon Outcomes Res. 2023 Feb;23(2):231-239. doi: 10.1080/14737167.2023.2161048. Epub 2022 Dec 28. Expert Rev Pharmacoecon Outcomes Res. 2023. PMID: 36541133
Treatment patterns and outcomes in older adults with castration-resistant prostate cancer: Analysis of an Australian real-world cohort.
Fernando M, Anton A, Weickhardt A, Azad AA, Uccellini A, Brown S, Wong S, Parente P, Shapiro J, Liow E, Torres J, Goh J, Parnis F, Steer C, Warren M, Gibbs P, Tran B. Fernando M, et al. Among authors: brown s. J Geriatr Oncol. 2023 Nov;14(8):101621. doi: 10.1016/j.jgo.2023.101621. Epub 2023 Sep 6. J Geriatr Oncol. 2023. PMID: 37683368
Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study.
Mooi J, Chionh F, Savas P, Da Gama Duarte J, Chong G, Brown S, Wong R, Price TJ, Wann A, Skrinos E, Mariadason JM, Tebbutt NC. Mooi J, et al. Among authors: brown s. Clin Cancer Res. 2021 Apr 15;27(8):2159-2167. doi: 10.1158/1078-0432.CCR-20-2714. Epub 2021 Jan 29. Clin Cancer Res. 2021. PMID: 33514526 Clinical Trial.
Author Correction: brainlife.io: a decentralized and open-source cloud platform to support neuroscience research.
Hayashi S, Caron BA, Heinsfeld AS, Vinci-Booher S, McPherson B, Bullock DN, Bertò G, Niso G, Hanekamp S, Levitas D, Ray K, MacKenzie A, Avesani P, Kitchell L, Leong JK, Nascimento-Silva F, Koudoro S, Willis H, Jolly JK, Pisner D, Zuidema TR, Kurzawski JW, Mikellidou K, Bussalb A, Chaumon M, George N, Rorden C, Victory C, Bhatia D, Aydogan DB, Yeh FF, Delogu F, Guaje J, Veraart J, Fischer J, Faskowitz J, Fabrega R, Hunt D, McKee S, Brown ST, Heyman S, Iacovella V, Mejia AF, Marinazzo D, Craddock RC, Olivetti E, Hanson JL, Garyfallidis E, Stanzione D, Carson J, Henschel R, Hancock DY, Stewart CA, Schnyer D, Eke DO, Poldrack RA, Bollmann S, Stewart A, Bridge H, Sani I, Freiwald WA, Puce A, Port NL, Pestilli F. Hayashi S, et al. Among authors: brown st. Nat Methods. 2024 May 7. doi: 10.1038/s41592-024-02296-5. Online ahead of print. Nat Methods. 2024. PMID: 38714873 No abstract available.
12,728 results
You have reached the last available page of results. Please see the User Guide for more information.